anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the use and application of two extracts, one of them animal: gonads of echinoderms such as sea urchin, starfish and holothurian. The other extract, vegetable, drawn from the plant and most especially from the fruit of Hibiscus esculentus of the mallow family, originating from Asia, is edible and hence non-toxic. It is an amber-yellow, viscous liquid obtained by boiling or pressing which has enriching, anti-irritation and anti-ageing properties. Alone, separately or in combination with other products, the extracts supply, in the case of sea urchin: vitamins and trace-elements including iodine. In the case of Hibiscus esculentus, its use leaves the skin smooth, satiny and radiant; the same results are obtained on the body, around the eyes, on the hands and on the hair. It leaves a film which protects against pollution and adverse weather conditions.
Rationale: Patients with CCD/MmD, NEM and CNM report symptoms of weakness in the arms and legs. Other symptoms include weakness of the respiratory, facial and swallowing muscles. No treatments are available for congenital myopathies (CM) to slow down or cure the disease. A few type I-II trials have taken place and more are expected. Therefore it is important to reach trial readiness. To create trial readiness, there is a need for natural history study to create a detailed report of the disease course and a selection of the most sensitive clinical and functional outcome measures and biomarkers. Besides muscle weakness, several patients report muscle fatigability. This has not been investigated systematically in CM. The lack of evidence calls for a cross-sectional study assessing muscle fatigability and neuromuscular transmission in CM.

Objectives: i) To assess the natural disease course of CCD/MmD, NEM and CNM during 24 months. ii) To select relevant and sensitive clinical and functional outcome measures and biomarkers. iii) To assess the severity of muscle fatigability in CCD/MmD, NEM and CNM.

Study design: Patients with a genetically confirmed CCD/MmD, NEM or CNM will be able to participate in this study. The study consist of 2 parts. Part 1: a prospective cohort study with 5 visits every 6 months, for a total of 2 years. 45 patients will be included for this part. Part 2: an observational study with 2 visits. For this part 75 patients will be included. There will be an overlap in patients for the two parts. So a total of approximately 100 patients will be included. A large set of tests will be performed to assess the full capabilities of the patient, e.g. muscle strength/endurance, muscle imaging (MRI/ultrasound), activities, walking ability, quality of life, muscle fatigability and the feeling of fatigue.
The appliance for holding a medicated pad in close contact with the body, uses a conventional leather belt (1) as an attachment device. This has a buckle (3) one end, with a pin (4) which fits into one of a set of holes (2) at the other end. A rigid plate (5) can be mounted on the belt by means of loops (6). On the other side of this plate is a bellows (11) carrying a sponge pad (15). The bellows forms a chamber to hold the medicated pad (12), while the pad is kept in contact with the skin of the user. The plate has a lapped hole (7) through it to hold the end of a pump tube (9) with a bulb (10) at the other end. This is used to inflate the bellows and hold the pad (15) tightly in position.
Patients receive enasidenib PO QD. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
The investigators expect to receive outpatient admissions in the hospital attached to China Medical University. Menopausal women aged 45-60 years old who have been diagnosed with insomnia who meet criteria of International Classification of Sleep Disorders (ICSD-3) will be randomly assigned for clinical trials. Patients will take two Valerian capsules (1000mg/day) per day for four weeks. Pittsburgh Sleep Index (PSQI) will be used to evaluate subjective sleep quality. TCM patterns will be evaluated by three physicians of TCM gynecology independently before and after taking Valeriana. The data will conduct a biological analysis to compare the difference in sleep quality between the trial group and the control group.
The present invention relates to the treatment of acidosis related diseases. In this study, the inventors have investigated how human monocytes adapt, survive and differentiate into macrophages under lactic acidosis. Experiments were conducted under atmospheric oxygen and in the presence of glucose, to rule out an effect of oxygen or glucose deprivation. Prolonged exposure to LA affected monocyte/macrophage metabolism. Extracellular acidosis induced mitochondrial membrane depolarization and significantly decreased nutrient consumption, resulting in a dependence of the macrophages on a transient phase of autophagy for survival. In fasting conditions, hepatocytes produce the ketone bodies acetoacetate (AcAc) and β-hydroxybutyrate (β-OHB) that constitute alternative fuel for extrahepatic cells. The inventors found here that AcAc protected the mitochondria from acidosis-induced depolarization and mitophagy, allowing the cells to continue to metabolize nutrients, thereby avoiding the need for self-catabolism to survive. Acetoacetate therefore appears to be a crucial alternative fuel metabolite of potential therapeutic interest to increase tissue tolerance to lactic acidosis. Thus, the invention relates to the acetoacetate (AcAc) for use in the treatment of acidosis related diseases.
Hepatitis-B virus infection is endemic in Taiwan with 90% of the adult population having been previously infected with HBV at some stage in their lives, and with approximately 15 - 20% of the general population being carriers of HBV surface antigen at time of writing. In 1984, Taiwan implemented a hepatitis-B vaccination program for high risk newborns. In 1986, the program was extended to all newborns. At the commencement of the program, the HBV carrier rate amongst children was 9.8 percent. Subsequently, from later reports (namely from the 5-, 10-, 15-, 16-,18-, and 20-year post mass HBV vaccination program commencement follow-up studies), the HBV infection and carrier rates would appear to have been declining continuously. However, the long-term efficacy of such vaccination still has remained as one of the main points of interests amongst Taiwan's public-health officials.

Previous researches indicated that hepatitis B surface antibody (HBsAb) acquired from vaccination would decline over time. However, whether the decline of HBsAb implicated loss of protection to hepatitis B infection remained controversial. Reports pertaining to previously immunized healthcare worker (HCW) found that protective HBsAb still persisted in 76% and 52% of HCW after 3 and 13 years respectively. Anamnestic response was also observed, though the study population were limited. Hepatitis B vaccination has been documented to provide protection to HBV infection for at least 15 years for various age groups. Those who were younger than 4 years had the most pronounced decline or protective HBsAb.

Our previous observations have demonstrated that the implementation of the HBV vaccination program since 1984 had reduced the transmission of HBV in Taiwan. However, an increase of prevalence rate of HBV natural infection (anti-HBc positivity) in 1987 cohort, which may suggest the possibility of protection of HBV mass vaccination has gradually decreasing through years. The waning-off of serum anti-HBs level to no protective level among half of our student population has occurred eighteen years after mass vaccination. As a result, the aim of this study is to observe and evaluate initiate serum anti-HBs titers during entrance health examination among undergraduate freshmen in a university who showed a complete 4-dose HBV vaccination in infancy and whose serum status was (1) HBsAg negative and anti-HBc negative and (2) anti-HBc positive alone. For those students whose anti-HBs \<10 mIU/ml, additional HBV vaccination boosters were given according to routine governmental suggested schedules. The anamnestic effect then is observed in both groups. The results of this study may contribute to the analysis of the effectiveness of anti-HBV vaccination twenty years after the commencement of the program and the necessity of initiating HBV booster program among Taiwanese young adults.
Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density \[EFD\] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. A thin spinal needle was inserted into the L3-4 spinal interspace, after numbing the area. Once cerebrospinal fluid was confirmed, a small dose of isobaric bupivacaine was injected into the spinal canal.
Mucopolysaccharidosis type VII (MPS VII) is an ultra-rare, life-threatening, progressive disease caused by genetic mutations that affect lysosomal storage/function. MPS VII has an estimated prevalence of <1:1,000,000 and accounts for <3% of all MPS diagnoses. Given the rarity of MPS VII, comprehensive information on the disease is limited and we present a review of the current understanding. In MPS VII, intracellular glycosaminoglycans accumulate due to a deficiency in the lysosomal enzyme that is responsible for their degradation, β-glucuronidase, which is encoded by the GUSB gene. MPS VII has a heterogeneous presentation. Features can manifest across multiple systems and can vary in severity, age of onset and progression. The single most distinguishing clinical feature of MPS VII is non-immune hydrops fetalis (NIHF), which presents during pregnancy. MPS VII usually presents within one month of life and become more prominent at 3 to 4 years of age; key features are skeletal deformities, hepatosplenomegaly, coarse facies, and cognitive impairment, although phenotypic variation is a hallmark. Current treatments include hematopoietic stem cell transplantation and enzyme replacement therapy with vestronidase alfa. Care should be individualized for each patient. Development of consensus guidelines for MPS VII management and treatment is needed, as consolidation of expert knowledge and experience (for example, through the MPS VII Disease Monitoring Program) may provide a significant positive impact to patients.
An image display system and method includes a tiling module, a closure module, a retiling module, and a mirroring module. Image display system displays studies on primary and supplemental displays in response to commands received from a user workstation. Display entities are displayed on display areas of primary and supplemental displays within display entity boxes that are defined by display entity layouts. As new display entities are added, they are added to the display areas in a preferred tiling format. Display entities are automatically closed when one display entity is dragged over another. Display entity boxes are dynamically resized which resulting in redefinition of display entity layouts. Various display entities can also be displayed on an original display and mirrored onto an adjacent display using an appropriate display protocol.
This is an observation of the current use of a transdermal preparation of Celecoxib 8% which is being used in the treatment of patients with primary OA of the knees. This transdermal celecoxib preparation is currently in use in multiple rheumatology clinics in southern Ontario, Canada. Only patients that have been prescribed the celecoxib cream will be approached for screening and subsequent study participation. The study is purely observational as the protocol does not dictate treatment or dose assignment. Subjects will be followed for 12 weeks. In addition to the baseline clinic visit, they will participate in 2 telephone calls where data will be collected on outcome assessments that measure disease severity. The data collected during those visits will be compared to baseline values of the same assessments.
The method for obtaining the sum of the modified peptides with antiviral properties consists in acylating peptides with the succinic anhydride. Papainand chemotrypsin are used for the hydrolyisus of the acylated peptides. The method may be used in medicine and veterinary for obtaining the preparation, which could be effective in parenteral treatment of viral infections such as influenza and herpes. The essence of the invention consists in producing acylated albumin followed by its enzymatic hydrolysis. The sum of the acidic peptides obtained is capable for inhibiting the activity of T-antigen and inhibiting the viral replication dependent on the nuclear products. The antiviral agent proposed is effective against several viral infections such as influenza and herpes. The agent is characterized by the broad spectrum of activity while its toxicity is rather low allowing for the use against several viruses whose replicative cycle is dependent on the nuclear products.
The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
PURPOSE: A composition and a cosmetic composition containing Psoraleae Semen ethanol extract for preventing and treating kidney cancer are provided to suppress kidney cancer cell growth. CONSTITUTION: A composition for preventing and treating kidney cancer contains Psoraleae Semen ethanol extract as an active ingredient, extracted at 50 Deg. C. for 24 hours. The ethanol is 95% ethanol. The composition also contains pharmaceutically acceptable carriers or diluents. A cosmetic composition contains the Psoraleae Semen ethanol extract and cosmetologically acceptable cosmetic additives. [Reference numerals] (AA) Relative cell survival rate
Intravenous use in eclampsia should be reserved for immediate control of life-threatening convulsions.

Parenteral use in the presence of renal insufficiency may lead to magnesium intoxication.

Warning: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur even at lower rates of administration.
Spongy cohesive gold for dental fillings is prepared by precipitating gold from a solution, heating the precipitate in a high boiling liquid, such as concentrated phosphoric acid or commercial (unpurified) sulphuric acid, at a temperature between 150 and 250 DEG C., and washing and drying the precipitate.  In use, the tooth cavity need not be dried and the gold is inserted by means of an instrument moistened with a dilute antiseptic solution and is compacted by pressure and burnished.  Preferably, a gold chloride solution is neutralized by an alkali, heated to 80 DEG  C. and the gold precipitated by oxalic acid or sodium nitrite added in excess.  The solution and precipitate are then boiled and any gold remaining in solution is precipitated by addition of oxalic acid if sodium nitrite was used for the first precipitation or by addition of sodium oxalate or an alkali if oxalic acid was used. The pH of the solution should be between 6 and 7 at this point. The liquid is then decanted off and the precipitate washed in water, heated to between 150 and 250 DEG C. in commercial sulphuric acid, repeatedly boiled and washed with distilled water, and dried below 100 DEG  C.  The treatment of gold precipitated by formaldehyde, formic acid or hydrogen peroxide is also referred to.  Specification 380,324 is referred to.ALSO:Spongy cohesive gold for dental purposes is prepared by precipitating gold from a solution, heating the precipitate in a high boiling liquid, such as concentrated phosphoric acid or commercial (unpurified) sulphuric acid, to a temperature between 150 and 250 DEG  C., and washing and drying the precipitate. Preferably a gold chloride solution is neutralized with alkali, heated to 80 DEG  C., and the gold precipitated by oxalic acid or sodium nitrate added in excess. The solution and precipitate are then boiled and any gold remaining in solution is precipitated by addition of oxalic acid if sodium nitrite was used for the first precipitation or by addition of sodium oxalate or an alkali if oxalic acid was used.  The pH of the solution should be between 6 and 7 at this point.  The liquid is then decanted off and the precipitate washed in water, heated to between 150 and 250 DEG  C. in commercial sulphuric acid, repeatedly boiled and washed with distilled water, and dried below 100 DEG  C.  The treatment of gold precipitated by formaldehyde, formic acid or hydrogen peroxide is also referred to.  Specification 380,324 is referred to.
Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.
The spinal accessory nerve, considered part of the eleventh cranial nerve, provides motor innervation to sternocleidomastoid and trapezius. A comprehensive literature review and two cadaveric dissections were undertaken. The spinal accessory nerve originates from the spinal accessory nucleus. Its rootlets unite and ascend between the denticulate ligament and dorsal spinal rootlets. Thereafter, it can anastomose with spinal roots, such as the McKenzie branch, and/or cranial roots. The spinal accessory nerve courses intracranially via foramen magnum and exits via jugular foramen, within which it usually lies anteriorly. Extracranially, it usually crosses anterior to the internal jugular vein and lies lateral to internal jugular vein deep to posterior belly of digastric. The spinal accessory nerve innervates sternocleidomastoid, receives numerous contributions in the posterior triangle and terminates within trapezius. Its posterior triangle course approximates a perpendicular bisection of the mastoid-mandibular angle line. The spinal accessory nerve contains sensory nociceptive fibres. Its cranial nerve classification is debated due to occasional non-fusion with the cranial root. Surgeons should familiarize themselves with the variable course of the spinal accessory nerve to minimize risk of injury. Patients with spinal accessory nerve injuries might require specialist pain management.
Specifically, the study is being conducted in 3 West African countries: Togo, Niger and Mali. A total of 4 orthopaedic centres are involved, whereby an equal number of patients are recruited everywhere.

There are 2 groups of patients, those who need a (knee) ankle-foot orthosis to move around (dynamic AFO/KAFO) and those who need a night splint to correct the ankle or knee position. All patients in the study will have a treatment route involving fitting a new traditional orthosis and a new 3D printed orthosis. The order of application of both treatments will be randomised in a crossover design. Patients will be measured at baseline after the first treatment period (3 weeks) and after the second treatment period (6 weeks). The primary outcome measures are different for both groups of patients: the walking speed when performing the 10-metre walk test in the patients wearing the dynamic AFO/KAFO, and the measured angle (of knee or ankle) in the patients wearing a night splint.
Motor Imagery (MI) is imagining an action in the mind without any explicit physical movement. MI is considered an "offline" process of the motor areas of the brain. Neuroimaging studies have shown that roughly the same neural structures play a role both during movement execution and MI. Specifically, these neural structures; supplementary motor area (SMA), premotor cortex (PMC), and in a growing number of studies, primary motor cortex (M1), inferior parietal lobe (IPL), basal ganglia, and cerebellum. In MI, the changes occurring in the Central Nervous System (CNS), such as the activation of the structures responsible for planning the movement and the purpose for which the movement will be performed, are similar to physical movement, but with the inhibition of the last motor neuron (primary motor area) responsible for revealing the movement, the movement is not physically performed and the motor visualization occurs.

During motor imagery, monitoring the quality of the individual's imagery session is very important for the session's effectiveness. Additionally, studies have shown that giving the subject biofeedback regarding mental work can modulate the individual's mental work. For these purposes, the quality of an individual's motor imagery during a motor imagery session can be measured by biological measurement methods such as fMRI and autonomic nervous system response. In studies conducted on the autonomic nervous system response, changes in skin resistance and heart rate variations were observed. However, these methods are very costly and cannot be accessed in every clinic. In the literature, the Polar HRV device for measuring heart rate variability is a measuring device with proven validity and reliability and is easily accessible in terms of cost. However, we do not yet know whether Polar HRV is a valid and reliable measurement tool to measure the quality of an individual's imagery session during a motor imagery session.

This study aims to determine the effects of the individual's autonomic nervous system during the kinesthetic motor imagery session. To measure the responses and to investigate whether the polar HRV device is a valid and reliable tool.
The present disclosure provides an oat fermentation product, an oat product produced therefrom, a preparation method, and use thereof. The oat fermentation product is obtained by fermenting a fermentation solution comprising a fermentation substrate and a ferment. The fermentation substrate may include a partially hydrolyzed oat and an oat bran. The ferment includes Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus reuteri GL104, Lactobacillus plantarum LPL28 and Lactobacillus acidophilus NCFM. The oat fermentation product includes at least 11 mg/ml amino acids, galactose at a concentration of 2,000-100,000 ppm, and glucose at a concentration of at least 600 ppm. The oat fermentation product is rich in monosaccharides, amino acids, beta-glucan, and other phytonutrients, which are easily absorbed and utilized by gut. The fermentation of specific strains beneficially provides an organoleptically pleasant product that has an appropriate acidity and is fragrant, glutinous, and delicious.